Investors purchased shares of Becton, Dickinson and Company (NYSE:BDX) on weakness during trading on Monday. $44.38 million flowed into the stock on the tick-up and $30.44 million flowed out of the stock on the tick-down, for a money net flow of $13.94 million into the stock. Of all stocks tracked, Becton, Dickinson and had the 28th highest net in-flow for the day. Becton, Dickinson and traded down ($0.29) for the day and closed at $199.15

A number of brokerages have issued reports on BDX. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a research note on Monday, August 14th. Barclays PLC reissued an “equal weight” rating and set a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Finally, Zacks Investment Research lowered shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $195.79.

The stock’s 50 day moving average is $200.23 and its 200-day moving average is $190.52. The firm has a market capitalization of $45.53 billion, a price-to-earnings ratio of 57.94 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business had revenue of $3.04 billion during the quarter, compared to analysts’ expectations of $3.06 billion. During the same quarter in the prior year, the company posted $2.35 earnings per share. The firm’s revenue was down 5.1% on a year-over-year basis. On average, equities research analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.46%. The ex-dividend date is Thursday, September 7th. Becton, Dickinson and’s payout ratio is 83.43%.

In other Becton, Dickinson and news, insider Ellen R. Strahlman sold 9,283 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $198.21, for a total value of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares in the company, valued at $5,279,917.98. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Nabil Shabshab sold 6,149 shares of the stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total transaction of $1,240,622.24. Following the completion of the sale, the insider now owns 15,648 shares of the company’s stock, valued at approximately $3,157,140.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,605 shares of company stock valued at $9,718,986. Corporate insiders own 1.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. North Star Investment Management Corp. lifted its stake in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock valued at $101,000 after acquiring an additional 18 shares during the last quarter. Almanack Investment Partners LLC. acquired a new stake in Becton, Dickinson and in the first quarter valued at $105,000. Parkside Financial Bank & Trust lifted its stake in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 9 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in Becton, Dickinson and by 55.8% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock valued at $131,000 after acquiring an additional 240 shares during the last quarter. Finally, Financial Architects Inc lifted its stake in Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock valued at $124,000 after acquiring an additional 261 shares during the last quarter. Hedge funds and other institutional investors own 87.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Investors Buy Shares of Becton, Dickinson and Company (BDX) on Weakness” was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.dailypolitical.com/2017/09/06/investors-buy-shares-of-becton-dickinson-and-company-bdx-on-weakness-3.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.